Trial · NCT00679302
Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
NCT00679302, Phase 4, Completed, St. Louis University; results first posted 2014-04-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management. Trials, record NCT00679302. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00679302
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
- NCT number
- NCT00679302
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 161 participants, actual
- Lead sponsor
- St. Louis University
- Conditions
- Skin Diseases, Infectious
- Interventions
- Trimethoprim-sulfamethoxazole, Placebo group
- First posted
- 2008-05-16
- Last updated
- 2018-05-04
- Results first posted
- 2014-04-29
- Limitations and caveats
- Small sample size with large number of loss to follow up at the 3 month mark.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Skin Abscess Resolution | 10-14 days | |
| Secondary | New Lesion Development and Spread of Skin Abscesses (on Subject) | 10-14 days and 3 month | The secondary outcomes of interest included the development of new lesions at a different site (\>5cm away from original skin abscess) on day 10 clinical follow-up or self-report and 3 month telephone follow-up. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Skin Abscess Resolution | 10-14 days | participants | NUMBER | |
| SECONDARY | New Lesion Development and Spread of Skin Abscesses (on Subject) | 10-14 days and 3 month | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Skin Abscess Resolution | Placebo Group | 4 | 95% Confidence Interval 1.2 to 6.8 | participants | |
| Skin Abscess Resolution | Antibiotic Group | 3 | 95% Confidence Interval 1.2 to 6.8 | participants | |
| New Lesion Development and Spread of Skin Abscesses (on Subject) | Placebo Group | 15 | participants | ||
| New Lesion Development and Spread of Skin Abscesses (on Subject) | Antibiotic Group | 13 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo Group | 84 | |
| Overall Study | STARTED | Antibiotic Group | 77 | |
| Overall Study | COMPLETED | Placebo Group | 76 | |
| Overall Study | COMPLETED | Antibiotic Group | 73 | |
| Overall Study | NOT COMPLETED | Placebo Group | 8 | |
| Overall Study | NOT COMPLETED | Antibiotic Group | 4 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | rash | Skin and subcutaneous tissue disorders | Placebo Group | 0 | 76 | 0 |
| other | rash | Skin and subcutaneous tissue disorders | Antibiotic Group | 3 | 73 | 3 |
| other | diarrhea | Gastrointestinal disorders | Placebo Group | 4 | 76 | 4 |
| other | diarrhea | Gastrointestinal disorders | Antibiotic Group | 3 | 73 | 3 |
| other | vomiting | Gastrointestinal disorders | Placebo Group | 1 | 76 | 1 |
| other | vomiting | Gastrointestinal disorders | Antibiotic Group | 1 | 73 | 1 |
| other | vomiting and diarrhea | Gastrointestinal disorders | Placebo Group | 1 | 76 | 1 |
| other | vomiting and diarrhea | Gastrointestinal disorders | Antibiotic Group | 1 | 73 | 1 |
| other | bad taste | General disorders | Placebo Group | 1 | 76 | 1 |
| other | bad taste | General disorders | Antibiotic Group | 5 | 73 | 5 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo Group | ||
| Total, all-cause mortality | Antibiotic Group | ||
| Total, other adverse events | Placebo Group | 7 | 76 |
| Total, other adverse events | Antibiotic Group | 13 | 73 |
| Total, serious adverse events | Placebo Group | 0 | 76 |
| Total, serious adverse events | Antibiotic Group | 0 | 73 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Antibiotic Group vs Placebo Group: New Lesion Development and Spread of Skin Abscesses (on Subject) | Trial comparisons |
| Antibiotic Group vs Placebo Group: Skin Abscess Resolution | Trial comparisons |
| Antibiotic Group vs Placebo Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00679302
GET https://conductscience.org/api/trials/v1/NCT00679302/registered